The expression level of Bcl-2 was significant increased in AML (median: 0.53) (p < 0.0001) and CML (median: 0.33) (p = 0.007) groups compared with HI group (median: 0.11). This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.